-
Product Insights
Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Multiple Sclerosis Pipeline Drugs Development Market Report Overview Multiple sclerosis (MS) is a potentially debilitating disease in which the body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between the brain, spinal cord, and other areas of the body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of the body, fatigue, and slurred speech. The...
-
Product Insights
Chlamydia Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Chlamydia occurs with multiple symptoms including a burning feeling during urination, discharge from the penis or vagina, pain in the lower abdomen, bleeding between periods, and pain and swelling around the testicles. Treatment includes antibiotics and pain medicine. The Chlamydia Infections pipeline drugs market research report provides an analysis of the Chlamydia Infections drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers the descriptive pharmacological action of...
-
Product Insights
Psoriasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Psoriasis is a chronic skin condition caused by an overactive immune system. Symptoms of the disease include shedding of cells, flared-up skin, itchiness, burning sensation, and swollen and stiff joints. Predisposing factors include heredity, side effects of certain medicines, stress, infections, and environmental conditions. The condition may be controlled by topical or systemic medications and phototherapy. The Psoriasis pipeline market research report provides comprehensive information on the therapeutics under development for Psoriasis, complete with analysis by stage of development, drug...
-
Product Insights
Nuclear Factor Erythroid 2 Related Factor 2 (HEBP1 or Nuclear Factor Erythroid Derived 2 Like 2 or NFE2L2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Nuclear factor (erythroid-derived 2)-like 2 or Nrf2 is a transcription factor encoded by the NFE2L2 gene. It binds to antioxidant response elements in the promoter regions of target genes. It is important for the coordinated up-regulation of genes in response to oxidative stress. It is involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region. The Nuclear Factor Erythroid 2 Related Factor 2 - Drugs...